Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results